🇺🇸 FDA
Patent

US 12359178

Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase

granted A61KA61K38/465A61P

Quick answer

US patent 12359178 (Methods and compositions for treatment of hunter syndrome comprising iduronate-2-sulfatase) held by Takeda Pharmaceutical Company Limited expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K38/465, A61P, A61P25/00, A61P3/00